Tejara Capital Ltd acquired a new position in Becton, Dickinson and Company (NYSE:BDX – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 5,400 shares of the medical instruments supplier’s stock, valued at approximately $1,048,000.
Other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC increased its holdings in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares during the period. Oppenheimer Asset Management Inc. raised its stake in Becton, Dickinson and Company by 71.4% in the third quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier’s stock worth $15,471,000 after buying an additional 34,437 shares in the last quarter. Transcend Capital Advisors LLC lifted its holdings in Becton, Dickinson and Company by 88.2% during the third quarter. Transcend Capital Advisors LLC now owns 5,794 shares of the medical instruments supplier’s stock worth $1,084,000 after buying an additional 2,715 shares during the period. Belpointe Asset Management LLC bought a new stake in Becton, Dickinson and Company during the 3rd quarter valued at $650,000. Finally, Assetmark Inc. boosted its position in Becton, Dickinson and Company by 49.5% during the 3rd quarter. Assetmark Inc. now owns 225,967 shares of the medical instruments supplier’s stock valued at $42,294,000 after acquiring an additional 74,795 shares in the last quarter. 86.97% of the stock is owned by institutional investors.
Becton, Dickinson and Company Stock Up 0.2%
Shares of BDX stock opened at $144.50 on Friday. The stock’s fifty day moving average price is $155.37 and its 200 day moving average price is $179.58. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The company has a market cap of $39.81 billion, a price-to-earnings ratio of 36.58, a price-to-earnings-growth ratio of 10.21 and a beta of 0.22. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55.
Becton, Dickinson and Company declared that its board has initiated a stock repurchase plan on Tuesday, January 27th that permits the company to repurchase $10.00 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.
Becton, Dickinson and Company Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be paid a $1.05 dividend. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.9%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 106.33%.
Insiders Place Their Bets
In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the sale, the director owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last quarter, insiders have sold 1,102 shares of company stock worth $198,909. 0.40% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
BDX has been the subject of several recent research reports. Wells Fargo & Company boosted their price target on Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. TD Cowen cut their target price on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a research note on Monday, May 4th. Citigroup reduced their target price on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Piper Sandler decreased their price target on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Finally, Royal Bank Of Canada set a $175.00 price objective on shares of Becton, Dickinson and Company in a research report on Tuesday, April 14th. Seven research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $184.86.
Get Our Latest Report on Becton, Dickinson and Company
Becton, Dickinson and Company Company Profile
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Stories
- Five stocks we like better than Becton, Dickinson and Company
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
